Clinical Trial: A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients
Brief Summary: This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
Detailed Summary:
Sponsor: Lux Biosciences, Inc.
Current Primary Outcome: ocular irritation [ Time Frame: 12 hours ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Lux Biosciences, Inc.
Dates:
Date Received: February 24, 2009
Date Started: February 2009
Date Completion:
Last Updated: June 21, 2012
Last Verified: June 2012